Log in to save to my catalogue

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of t...

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of t...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10504076

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

About this item

Full title

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Publisher

New York: Nature Publishing Group US

Journal title

Nature medicine, 2023-09, Vol.29 (9), p.2358-2365

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This prespecified analysis examined the effects of semaglutide on dual primary endpoints (change in Kansas City Cardiomyopathy Questio...

Alternative Titles

Full title

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10504076

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10504076

Other Identifiers

ISSN

1078-8956,1546-170X

E-ISSN

1546-170X

DOI

10.1038/s41591-023-02526-x

How to access this item